HeartSciences released MyoVista Insights version 1.3 with an AI-ECG Algorithm Marketplace, making Bunkerhill Health's FDA cleared ECG-EF algorithm for detecting reduced left ventricular ejection fraction available through the platform. Both companies are indexed here, making this a distribution relationship between two vendors in this index: Bunkerhill developed and cleared the algorithm, HeartSciences distributes it.
Our readThis is a distribution event rather than a clearance, and the distinction matters. The cleared algorithm belongs to Bunkerhill; HeartSciences supplies the platform that delivers it. For a community hospital, critical access hospital, or primary care practice, that is the substantive change: a cleared AI-ECG model detecting reduced ejection fraction becomes reachable without a direct enterprise agreement with the algorithm developer, in a setting where echocardiography is often not readily available. Buyers evaluating MyoVista Insights should be clear that the AI they gain access to today is Bunkerhill's, since HeartSciences' own algorithms for impaired cardiac relaxation and low ejection fraction remain in development and unsubmitted or in pre submission. Assistive AI-ECG assessments are reimbursable under the Hospital Outpatient Prospective Payment System at APC 5734.